Ravi Salgia - Publications

Affiliations: 
Cancer Biology University of Chicago, Chicago, IL 
Area:
Oncology, Molecular Biology

59 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Salgia R, et al. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6099. PMID 30510088 DOI: 10.1158/1078-0432.CCR-18-3194  0.32
2018 Salgia R, Kulkarni P, Gill PS. EphB4: A promising target for upper Aerodigestive malignancies. Biochimica Et Biophysica Acta. PMID 29369779 DOI: 10.1016/j.bbcan.2018.01.003  0.32
2016 Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Letters. PMID 27450722 DOI: 10.1016/j.canlet.2016.07.021  0.32
2016 Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. PMID 27244893 DOI: 10.18632/oncotarget.9640  0.32
2016 Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. PMID 26980710 DOI: 10.18632/oncotarget.8040  0.32
2016 Vigneswaran J, Tan YC, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, ... ... Salgia R, et al. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. PMID 26934441 DOI: 10.18632/oncotarget.7739  0.32
2015 Allen MJ, Kanteti R, Riehm JJ, El-Hashani E, Salgia R. Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 26282382 DOI: 10.1016/j.nano.2015.07.014  0.32
2015 Nocula-Lugowska M, Lugowski M, Salgia R, Kossiakoff AA. Engineering synthetic antibody inhibitors specific for LD2 or LD4 motifs of paxillin. Journal of Molecular Biology. PMID 26087144 DOI: 10.1016/j.jmb.2015.06.004  0.32
2015 Ferguson BD, Carol Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, John Iafrate A, Gill PS, Salgia R. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Scientific Reports. 5: 10641. PMID 26073592 DOI: 10.1038/srep10641  0.32
2015 Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SI, Salgia R, Brennan T, Chalmers ZR, et al. Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery. PMID 25971938 DOI: 10.1158/2159-8290.CD-15-0285  0.32
2015 Zhang H, Wroblewski K, Jiang Y, Penney BC, Appelbaum D, Simon CA, Salgia R, Pu Y. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 89: 43-9. PMID 25936471 DOI: 10.1016/j.lungcan.2015.03.023  0.32
2015 Fu P, Usatyuk PV, Lele A, Harijith A, Gregorio CC, Garcia JG, Salgia R, Natarajan V. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology. 308: L1025-38. PMID 25795725 DOI: 10.1152/ajplung.00306.2014  0.32
2015 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Salgia R, et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2601-12. PMID 25767293 DOI: 10.1158/1078-0432.CCR-14-2648  0.32
2015 Dikopf A, Wood K, Salgia R. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opinion On Drug Safety. 14: 485-93. PMID 25659177 DOI: 10.1517/14740338.2015.1007040  0.32
2015 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: S1-63. PMID 25535693 DOI: 10.1097/JTO.0000000000000405  0.32
2015 Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Molecular Cancer Therapeutics. 14: 461-9. PMID 25504632 DOI: 10.1158/1535-7163.MCT-14-0431  0.32
2015 Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, ... ... Salgia R, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 870-81. PMID 25492084 DOI: 10.1158/1078-0432.CCR-14-2481  0.32
2014 Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors (Chur, Switzerland). 32: 202-6. PMID 25391996 DOI: 10.3109/08977194.2014.980904  0.32
2014 Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Molecular Cancer. 13: 242. PMID 25344208 DOI: 10.1186/1476-4598-13-242  0.32
2014 Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, ... Salgia R, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6336-45. PMID 25326232 DOI: 10.1158/1078-0432.CCR-14-1293  0.32
2014 Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England Journal of Medicine. 371: 1963-71. PMID 25264305 DOI: 10.1056/NEJMoa1406766  0.32
2014 Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. Plos One. 9: e105919. PMID 25221930 DOI: 10.1371/journal.pone.0105919  0.32
2014 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Research. 74: 5152-64. PMID 25136066 DOI: 10.1158/0008-5472.CAN-14-0294  0.32
2014 Lukas RV, Lesniak MS, Salgia R. Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. Cns Oncology. 3: 61-75. PMID 25054901 DOI: 10.2217/cns.13.66  0.32
2014 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Molecular Cancer Therapeutics. 13: 1356-68. PMID 24634415 DOI: 10.1158/1535-7163.MCT-13-1021  0.32
2014 Usatyuk PV, Fu P, Mohan V, Epshtein Y, Jacobson JR, Gomez-Cambronero J, Wary KK, Bindokas V, Dudek SM, Salgia R, Garcia JG, Natarajan V. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. The Journal of Biological Chemistry. 289: 13476-91. PMID 24634221 DOI: 10.1074/jbc.M113.527556  0.32
2014 Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1666-75. PMID 24493831 DOI: 10.1158/1078-0432.CCR-13-2070  0.32
2014 Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. Bmc Cancer. 14: 5. PMID 24386952 DOI: 10.1186/1471-2407-14-5  0.32
2014 Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Molecular Cancer Therapeutics. 13: 576-84. PMID 24327519 DOI: 10.1158/1535-7163.MCT-13-0109  0.32
2014 Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Advances in Experimental Medicine and Biology. 799: 85-117. PMID 24292963 DOI: 10.1007/978-1-4614-8778-4_5  0.32
2014 Puri N, Pitman RT, Mulnix RE, Erickson T, Iness AN, Vitali C, Zhao Y, Salgia R. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Letters. 343: 14-23. PMID 24041868 DOI: 10.1016/j.canlet.2013.09.010  0.32
2013 Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. Journal of Carcinogenesis. 12: 20. PMID 24319345 DOI: 10.4103/1477-3163.120632  0.32
2013 Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, ... ... Salgia R, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. Plos One. 8: e67668. PMID 23844053 DOI: 10.1371/journal.pone.0067668  0.32
2013 Shieh JM, Tang YA, Yang TH, Chen CY, Hsu HS, Tan YH, Salgia R, Wang YC. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. International Journal of Medical Sciences. 10: 988-94. PMID 23801885 DOI: 10.7150/ijms.5944  0.32
2013 Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, ... ... Salgia R, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biology & Therapy. 14: 679-91. PMID 23792636 DOI: 10.4161/cbt.25091  0.32
2013 Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. EphB4 as a therapeutic target in mesothelioma. Bmc Cancer. 13: 269. PMID 23721559 DOI: 10.1186/1471-2407-13-269  0.32
2013 Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 81: 138-41. PMID 23628526 DOI: 10.1016/j.lungcan.2013.03.020  0.32
2013 Zhao Y, Zhao J, Mialki RK, Wei J, Spannhake EW, Salgia R, Natarajan V. Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. American Journal of Physiology. Lung Cellular and Molecular Physiology. 305: L56-63. PMID 23624790 DOI: 10.1152/ajplung.00417.2012  0.32
2013 Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: e254-8. PMID 23610116 DOI: 10.1200/JCO.2012.46.4289  0.32
2013 Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3068-77. PMID 23553849 DOI: 10.1158/1078-0432.CCR-12-3381  0.32
2013 Ephstein Y, Singleton PA, Chen W, Wang L, Salgia R, Kanteti P, Dudek SM, Garcia JG, Jacobson JR. Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity. The Journal of Biological Chemistry. 288: 2191-200. PMID 23212923 DOI: 10.1074/jbc.M112.404780  0.32
2013 Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, ... ... Salgia R, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Research. 73: 184-94. PMID 23100466 DOI: 10.1158/0008-5472.CAN-12-0915  0.32
2012 Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, ... ... Salgia R, et al. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. Bmj Open. 2. PMID 23103606 DOI: 10.1136/bmjopen-2012-001620  0.32
2012 Mollberg NM, Parsad NM, Armato SG, Vigneswaran J, Kindler HL, Sensakovic WF, Salgia R, Silverstein JC, Vigneswaran WT. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. International Surgery. 97: 65-70. PMID 23102002 DOI: 10.9738/CC66.1  0.32
2012 Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, Kanteti A, Ma W, He D, Husain AN, Kindler HL, Kanteti P, Salgia R, Natarajan V. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. Plos One. 7: e45330. PMID 23028939 DOI: 10.1371/journal.pone.0045330  0.32
2012 Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet. Oncology. 13: 1011-9. PMID 22954507 DOI: 10.1016/S1470-2045(12)70344-3  0.32
2012 Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, et al. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 856-65. PMID 22722787 DOI: 10.1097/JTO.0b013e31824c943f  0.32
2012 Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. The Journal of Thoracic and Cardiovascular Surgery. 144: 33-8. PMID 22710039 DOI: 10.1016/j.jtcvs.2012.05.060  0.32
2012 Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Sugarbaker DJ, Swanson SJ, Travis WD, Jaklitsch MT. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. The Journal of Thoracic and Cardiovascular Surgery. 144: 25-32. PMID 22710038 DOI: 10.1016/j.jtcvs.2012.05.059  0.32
2012 Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R. Differential expression of RON in small and non-small cell lung cancers. Genes, Chromosomes & Cancer. 51: 841-51. PMID 22585712 DOI: 10.1002/gcc.21968  0.32
2012 Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, Archer SL. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 2175-86. PMID 22321727 DOI: 10.1096/fj.11-196543  0.32
2012 Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 31: 15-24. PMID 22123719 DOI: 10.1097/PGP.0b013e318220ba16  0.32
2012 Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clinical Lung Cancer. 13: 123-8. PMID 22100149 DOI: 10.1016/j.cllc.2011.10.001  0.32
2012 Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 39: 27-38. PMID 21946983 DOI: 10.1007/s00259-011-1934-6  0.32
2011 Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4803-10. PMID 22042947 DOI: 10.1200/JCO.2011.35.4928  0.32
2011 Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, ... ... Salgia R, et al. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. Journal of Clinical Bioinformatics. 1: 1-11. PMID 21603121 DOI: 10.1186/2043-9113-1-8  0.32
2010 Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. The Journal of Biological Chemistry. 285: 18575-85. PMID 20360610 DOI: 10.1074/jbc.M109.075085  0.32
2009 Faoro L, Cervantes GM, Ferguson BD, Seiwert TY, Yala S, Vigneswaran WT, Westerhoff M, Tretiakova MS, Ferguson MK, Moura GL, Husain AN, Vokes EE, Salgia R. MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. Journal of Carcinogenesis. 8: 15. PMID 19955662 DOI: 10.4103/1477-3163.57857  0.32
2008 Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia R. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biology & Therapy. 7: 856-63. PMID 18340114 DOI: 10.4161/cbt.7.6.5842  0.32
Show low-probability matches.